Celebrating our 25TH ANNIVERSARY

Fresenius Medical Care was formed 25 years ago, and we are now the world’s largest dialysis provider. Join us as we celebrate our achievements and look ahead to the next 25 years of possibilities. For patients. For employees. For healthcare.

1990's

1996

Fresenius Medical Care North America (FMCNA) was formed with the merger of Fresenius USA, Inc., and National Medical Care’s North American dialysis business, becoming the continent’s leading dialysis provider and renal products manufacturer.

1997

Acquired Spectra Laboratories, Inc., the largest independent kidney dialysis lab in the U.S.

1997

Entered a joint venture with Beth Israel Medical Center, forming the Renal Research Institute.

2000's

2003

Launched the Advanced Renal Education Program (AREP) to assist nephrologists and professional dialysis staff in improving clinical outcomes and standards of practice.

2006

Entered the renal pharmaceuticals market with the acquisition of phosphate binder PhosLo®. PhosLo is a calcium acetate phosphate binder for oral application in end stage renal disease patients.

2006

Acquired dialysis provider Renal Care Group, a specialized dialysis services company that provided care to patients with kidney disease.

2008

Entered into a licensing agreement for Venofer® to treat iron deficiency anemia experienced by dialysis patients.

2009

Fresenius Renal Pharmaceuticals launched an authorized generic equivalent of PhosLo in partnership with Sandoz Pharmaceutical company.

2009

Acquired Nashville-based Health IT Services Group, bringing Acumen nEHR — the first nephrology-specific electronic health record — into the organization.

2009

Launched FreseniusRx , enabling patients to order and receive medications and supplies directly from specially trained renal pharmacists.

2010's

2010

Extended cooperation with pharmaceutical company Galencia and founded Vifor Fresenius Medical Care Renal Pharma (VFMCRP), to develop and market pharmaceutical therapies for patients with chronic kidney disease.

2011

Acquired American Access Care Holdings to enhance access to high-quality outpatient vascular care.

2011

Acquired Liberty Dialysis Holdings, renowned for its home dialysis programs and efficient hemodialysis healthcare model.

2014

Fresenius Renal Pharmaceuticals launched Velphoro®, a phosphate binder used in the treatment of hyperphosphatemia in patients who receive dialysis.

2014

Acquired National Cardiovascular Partners, the leading operator of endovascular, vascular, and cardiovascular services in the outpatient setting.

2016

Renal Therapies Group introduced the CLiC™ device, part of the Crit-Line® technology product line. The CLiC device non-invasively measures hematocrit, oxygen saturation, and percent change in intravascular blood volume during a patient’s hemodialysis treatment.

2016

Launched Fresenius Kidney Care as a division of Fresenius Medical Care North America, focused on education for people at all stages of kidney disease and dialysis services.

2017

Entered into an agreement with Humana to provide value based care services to Humana members living with end stage renal disease.

2017

Partnered with Cigna to launch a national program to drive quality and lower the cost of care for people with end stage renal disease undergoing dialysis.

2017

During a record-setting hurricane season, our Disaster Response Team mobilized ahead of hurricanes Irma, Harvey, and Maria, ensuring our dialysis patients received the life-sustaining care they needed and our employees were safe and supported.

2017

Launched Fresenius Kidney Care’s kidney disease education class, a free, expert-led class that helps people learn more about kidney disease and their treatment options — including transplant and home dialysis.

2018

Fresenius Medical Care and Humacyte, Inc. — a medical research, discovery, and development company focused on regenerative medicine — announced a strategic global partnership.

2018

Launched the Fresenius Medical Care Foundation, a nonprofit created to address the environmental, social, and economic conditions that increase the risk for chronic kidney disease.

2019

Broke ground on a new distribution center in Knoxville, TN, supporting efforts to increase the supplies and timing for the growing number of patients who choose home dialysis. 

2019

Invested in BioIntelliSense, to improve remote patient monitoring, interventions, and outcomes for people living with kidney disease and other chronic illnesses.

2019

Invested in BioIntelliSense, to improve remote patient monitoring, interventions, and outcomes for people living with kidney disease and other chronic illnesses.

2019

Formed InterWell Health, bringing together nephrologists to provide population health management and a full continuum of care for patients with chronic kidney disease.

2019

Acquired NxStage Medical, Inc., enhancing our patients’ choice of dialysis treatment modality and signifying the future of home therapies.

2019

Renal Therapies Group launched the 2008T BlueStar™ hemodialysis machine across the U.S., providing the most comprehensive upgrade in company history with evolved technology and elevated performance.

2020's

2020

Expanded collaboration with Humana to improve the health of eligible Humana Medicare Advantage and commercial members with chronic kidney disease and end stage renal disease through more coordinated, holistic care.

2020

Provided support to our employees during COVID-19 including child care stipends, supplemental pay, as well as procuring personal protective equipment well in advance of the onset of the pandemic.

2020

Achieved record growth of home dialysis treatments with an annual increase of 14 percent, and a 37 percent increase in the adoption of home hemodialysis.

2020

Fresenius Kidney Care announced plans to open more than 100 new Transitional Care Units to help people recently diagnosed with kidney failure learn about available treatment options, including home dialysis.

2020

The National Intensive Renal Care Reserve was formed in response to COVID-19, to provide additional dialysis machines for the nation’s hospitals due to an increase in patients with acute kidney injury.

2020

The U.S. Food and Drug Administration (FDA) cleared Novalung®, a heart and lung therapy system for the treatment of acute respiratory and acute cardiopulmonary failure.

2020

Provided $1.5 million in financial assistance to eligible employees impacted by unforeseen disaster or hardship situations through our CARES fund.

2021

For the fifth consecutive year, Fresenius Kidney Care demonstrated its continued success in achieving 5-Diamond status in all participating dialysis centers, reinforcing our commitment to promote, enhance, and raise awareness about the importance of safety.

2021

COVID-19 vaccines allocated to dialysis centers nationwide to support people with kidney failure who are at a high risk of complications from COVID-19. The plan also addressed health equity by reaching a high percentage of ethnic minorities with chronic kidney disease. 

2021

Spectra Laboratories division opened its largest and most state-of-the-art facility in Mississippi, offering faster turnaround times. 

2021

Frenova division enrolls dialysis patients in initiative to build the world’s largest genomic registry targeting kidney disease.

2021

Renal Therapies Group’s customer support team named a J.D. Power Certified Customer Service Program recipient for 2020.*

*Fresenius Renal Therapies Group has been recognized by J.D. Power for providing "An Outstanding Customer Service Experience for Phone Support.”

2021

Renal Therapies Group introduced the Kinexus™ Therapy Management Platform, a cloud-based connected health platform that supports the management of home peritoneal dialysis therapy for patients using the Liberty® Select cycler.

2021

Our innovative Fresenius Kidney Care nurse residency program announced a milestone of 175 graduates, with 250 nurses on track for 2021 and 500 in 2022. The development program is for graduate nurses and is the first of its kind in dialysis.